Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
boston top stories
deals
fda
genentech
2
×
life sciences
national blog main
national top stories
roche
san francisco blog main
avapritinib
blueprint medicines
cancer
cancer immunotherapy
center for medicare and medicaid services
clinical trials
companion diagnostic
cstone pharmaceuticals
daniel o'day
eli lilly
european medicines agency
fisogatinib
flatiron health
foundation medicine
foundationone cdx
foundationone heme
hepatocellular carcinoma
investing
jeff albers
medullary thyroid cancer
new york blog main
non-small cell lung cancer
osimertinib
pralsetinib
rucaparib (rubraca)
san francisco top stories
selpercatinib
thermo fisher scientific
What
roche
2
×
acquire
agreed
approval
big
billion
blueprint
broad
cancer
candidate
confidence
currently
didn’t
drug
fda
foundation
gain
genentech
marketing
medicine
medicines
momentum
morning
muscle
pact
panels
pay
pays
picked
profiling
recently
redux
regulatory
remaining
rest
ret
review
share
stock
struggled
Language
unset
Current search:
roche
×
genentech
×
boston
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine